Arena (ARNA) Q4 Misses Expectations

Arena Pharmaceuticals, Inc. (ARNA) shares are down $0.08 to $4.20 in extended hours Monday after the company reported its fourth quarter earnings results.

The biopharmaceutical company reported earnings of ($0.15) per share on revenues of $9.2 million, up 41.5% from a year ago. Analysts were expecting EPS of ($0.11) on revenues of $11.01 million.

For full-year 2014, revenues totaled $37 million. Net loss was $60.5 million, or $0.28 per share.

On valuation measures, Arena Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 8.2 million shares, trade at a P/E to growth ratio of 0.94. The median Wall Street price target on the name is $7.75 with a high target of $9.00. Currently ticker boasts 3 ‘Buy’ endorsements, compared to 5 ’Holds’ and no ‘Sell’.

Profitability-wise, ARNA has a t-12 profit and operating margin of (151.35%) and (283.08%), respectively. The $942.09 million market cap company reported $163.20 million in cash vs. $71.29 million in debt in its most recent quarter.

ARNA currently prints a one year loss of about 34% and a year-to-date return of around 30%.

The chart below shows where the equity has traded over the last 52 weeks.

Arena Pharmaceuticals Inc. is a biopharmaceutical company that develops novel drugs targeting G protein-coupled receptors. The company was founded in 1997 and is based in San Diego, California.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.